Dilated Cardiomyopathy Clinical Trial
Official title:
Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy
Verified date | May 2014 |
Source | Xijing Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Ethics Committee |
Study type | Interventional |
Dilated cardiomyopathy (DCM) is a poorly understood cause of systolic heart failure and is
the most common indication for heart transplantation worldwide. Despite advances in medical
and device therapy, the 5-year mortality of patients with DCM remains high.
Patients diagnosed of dilated cardiomyopathy with a NYHA functional class of II to IV and
left ventricular ejection fraction(LVEF) <35% were selected for randomized controlled study
of the efficacy and safety of high dose Renin-angiotensin system (RAS) inhibitor (benazepril
or valsartan), in comparison with low dose RAS inhibitor(benazepril or valsartan) and
standard beta-adrenergic blocker therapy (metoprolol). The primary endpoint was all cause
death or admission for heart failure. Additional prespecified outcomes included all-cause
death, cardiovascular death, all-cause admission, heart failure admission. Secondary
cardiovascular outcomes included the changes from baseline to the last available observation
after treatment in NYHA functional class, quality-of-life scores, LVEF, LVEDD, mitral
regurgitation and wall-motion score index assessed by ECG. Adverse events were reported
during in-hospital observation and follow-ups.
Status | Completed |
Enrollment | 480 |
Est. completion date | December 2013 |
Est. primary completion date | July 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of dilated cardiomyopathy - Left ventricular ejection fraction < 35% - NYHA Functional classes of II-IV - Symptomatic but not rapidly deteriorating 1 month before enrollment - Signed informed consent Exclusion Criteria: - Contradictions and intolerance of the studied drugs: - supine systolic arterial blood pressure < 90 mmHg, - renal artery stenosis >50%, - pregnancy or lactation, - impaired renal function (estimated glomerular filtration rate < 60 ml/min/1.73m2, - impaired liver function (total bilirubin >2 times upper limit of normal, - serum aspartate AST or alanine ALT >3 times the upper limit of normal), - hemoglobin less than 8 mg/dl, hyperkalaemia (serum potassium >5.5mmol/l), - obstructive lung disease, - advanced atrioventricular block, - any co-morbidity with impact on survival, and - known intolerance to benazepril, valsartan and metoprolol succinate; - HF secondary to a known cause: - coronary artery disease based on coronary angiography (=50% stenosis in =1 of the major coronary arteries) and/or a history of myocardial infarction or angina pectoris, - acute or subacute stage of myocarditis, - primary valve disease, - diabetes mellitus, - excessive use of alcohol or illicit drugs; - Expected or performed cardiac resynchronization therapy and heart transplantation. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Xijing Hospital, Department of Cardiology | Xi'an |
Lead Sponsor | Collaborator |
---|---|
Xijing Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | All-cause mortality | 48 months after enrollment | No | |
Other | Cardiovascular death | 48 months after enrollment | No | |
Other | All-cause hospital admission | 48 months after enrollment | No | |
Other | Heart failure admission | 48 months after enrollment | No | |
Other | changes in mitral regurgitation | 12, 24 and 36 months after enrollment | No | |
Other | wall-motion score index | Wall motion score index (WMSI) was analyzed using an 11 segments model (3) (basal lateral, middle lateral, basal inferior, middle inferior, basal posterior interventricular septum, middle posterior interventricular septum, basal anterior free wall, middle anterior free wall, basal anterior interventricular septum, middle anterior interventricular septum and apex) with six segments each assigned to anterior and inferior regions, the apex being common. The motion of individual segments was graded as follows: normal 0, hypokinesia 1, akinesia 2, and dyskinesia 3. Global systolic wall motion score was calculated by dividing the total score by the number of segments analyzable. Results were only included when at least four segments from each of the anterior and inferior regions were analyzable. The lowest value of segment motion was chosen from the recorded motion amplitude of all 11 segments | 12, 24 and 36 months after enrollment | No |
Other | Adverse events | Hypotension Hyperkalaemia Renal impairment Liver dysfunction Nonfatal stroke Angioedema | 48 months after enrollment | Yes |
Primary | All cause death or admission for heart failure | Admission for heart failure was defined as a minimum of 24 h inpatient admission to any health-care facility, with the primary cause being treated for worsening heart failure and during which an additional diuretic drug, intravenous or oral nitrate, or intravenous inotropic agent was given. | 48 months after enrollment | No |
Secondary | Changes in NYHA functional class | 6,12, 24 and 36 months after enrollment | No | |
Secondary | Left-ventricular ejection fraction | Left ventricular ejection fraction (LVEF) were calculated from measurements of left ventricular end diastolic and end systolic volumes in apical 4 and 2 chamber views using the modified Simpson's rule according to current guidelines | 6,12, 24 and 36 months after enrollment | No |
Secondary | Left-ventricular end-diastolic diameter | 6, 12 , 24 and 36 months after enrollment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|
||
Recruiting |
NCT04982081 -
Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
|
Phase 1 | |
Not yet recruiting |
NCT04703751 -
Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents
|
N/A | |
Recruiting |
NCT01157299 -
Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO
|
N/A | |
Completed |
NCT00765518 -
Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
|
Phase 2 | |
Completed |
NCT02115581 -
Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
|
Phase 4 | |
Recruiting |
NCT04246450 -
Arrhythmic Risk Stratification in Nonischemic Dilated Cardiomyopathy
|
N/A | |
Recruiting |
NCT05799833 -
Low QRS Voltages in Young Healthy Individuals and Athletes
|
||
Recruiting |
NCT01914081 -
Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside
|
Phase 3 | |
Recruiting |
NCT02915718 -
A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy
|
N/A | |
Recruiting |
NCT03061994 -
Metabolomic Study of All-age Cardiomyopathy
|
N/A | |
Completed |
NCT03893760 -
Assessment of Right Ventricular Function in Advanced Heart Failure
|
||
Not yet recruiting |
NCT01219452 -
Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT02175836 -
Arrhythmia Prediction Trial
|
N/A | |
Active, not recruiting |
NCT00962364 -
Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
|
||
Recruiting |
NCT05026112 -
The Arrhythmogenic Potential of Midwall Septal Fibrosis in Dilated Cardiomyopathy
|
||
Recruiting |
NCT05237323 -
Micophenolate Mofetil Versus Azathioprine in Myocarditis
|
Phase 3 | |
Recruiting |
NCT04649034 -
Intraventricular Stasis In Cardiovascular Disease
|
||
Suspended |
NCT03071653 -
Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study
|
Phase 2 | |
Completed |
NCT02619825 -
Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie)
|
N/A |